お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
市場調査レポート
商品コード
934238

人工免疫調節療法:市場機会と治験の考察 (2026年)

Artificial Immune Modulation Therapy Market Opportunity & Clinical Trials Insight 2026

出版日: | 発行: KuicK Research | ページ情報: 英文 80 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.84円

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

人工免疫調節療法:市場機会と治験の考察 (2026年)
出版日: 2020年05月01日
発行: KuicK Research
ページ情報: 英文 80 Pages
納期: 即日から翌営業日
担当者のコメント
人工的に抗原を接種し、免疫を調節する人工免疫調節 (AIM) 療法の市場に着目し、パぷライン動向や市場促進、価格調査、課題などをまとめた最新調査レポートが、Kuick Research社よりリリースされました。まずはサンプルページで目次や概要をご案内させていただきますので、お問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の人工免疫調節 (AIM) 療法の市場について分析し、AIMの概要や診断・治療上の主な効果、現在開発中・治験中のパイプライン製品の概略、主な市場促進・抑制要因、全体的な市場規模の動向見通し、カテゴリー別の市場規模・価格動向の見通し、今後の市場機会などを調査しております。

目次

第1章 人工免疫調節ナノテクノロジー:概要

  • 人工免疫調節ナノテクノロジー:概要
  • 人工免疫調節の設計:免疫療法からの触発
  • T細胞の活性化に対する抗原提示細胞の影響

第2章 人工免疫調節プラットフォームの強化における、ナノテクノロジーの役割

  • 他の免疫療法の効率に貢献するナノ粒子
  • ナノテクノロジーと人工免疫変調の組み合わせに関連する利点

第3章 抗原提示細胞を操作するための合成免疫学

  • すでに利用可能な免疫療法のための合成免疫学
  • 人工免疫調節における合成免疫学の適格性と活用分野

第4章 各種の適応症のための人工免疫調節

  • 免疫-がんサイクルの関係
  • 癌に対する人工免疫調節の影響
  • 他の適応症に対する人工免疫調節の影響

第5章 独自の人工免疫変調プラットフォームのためのT細胞濃縮・拡張 (E+E) 技術

第6章 人工免疫調節製品のための、NexImmuneの治験

  • NEX-001およびNEX-003:急性骨髄性白血病向け
    • 概観
    • 臨床的洞察
  • NEX-002:多発性骨髄腫向け
    • 概観
    • 臨床的洞察

第7章 人工免疫調節療法の拡大に向けた、最近の傾向と機会

  • 世界のがん統計
  • 免疫療法治療の人気の高まり
  • 製薬企業別高い適応性
  • 他のがん治療法と組み合わせた免疫療法

第8章 人工免疫調節薬の商機

  • 人工免疫調節 (AIM) 製品の商業的成功を推計するための免疫療法と価格調査
    • CAR-T細胞療法とその製品
    • 腫瘍浸潤リンパ球免疫療法
  • AIM療法の見積もり価格

第9章 人工免疫変調の結果触発される市場促進と課題

  • 人工免疫調節の促進要因
  • 人工免疫調節の課題

第10章 人工免疫調節の今後の方向性

  • 免疫療法の新たな収益源の開拓
  • 人工免疫調節:将来の地域市場の情勢

第11章 競争環境

図表

List of Figures

  • Figure 1-1: Natural Antigen Presentation by Antigen Presenting Cells
  • Figure 1-2: Artificial Immune Modulation Antigen Presentation
  • Figure 1-3: Types of Therapies Based on Immunotherapy Principle
  • Figure 1-4: Results of Antigen Presentation on T-Cells by Antigen Presenting Cells
  • Figure 1-5: US - Population of Men & Women Living with Auto-Immune Diseases (Million), 2020
  • Figure 1-6: US - Cancer Statistics (Million), 2019
  • Figure 2-1: Different Configurations Used in Nano Bio Materials for Medical or Biological Issues
  • Figure 2-2: Applications of Nanotechnology in Medicines
  • Figure 2-3: Potential Contribution of Nanoparticles to Immunotherapies
  • Figure 3-1: Synthetic Immunology Working on Immune Cells
  • Figure 3-2: Potential Addition of Functions to Engineered Immune Cells
  • Figure 3-3: Synthetic Immunology & Artificial Immune Modulation Combination
  • Figure 4 1: Representation of Immune System Attacking Cancer Cells with the help of Antigen Presenting Cells
  • Figure 4-2: North America - Population above 65 Years of Age (Million), 2018
  • Figure 4-3: Artificial Immune Modulation Against Cancer
  • Figure 4-4: US- Auto-Immune Diseases Statistics (Million), 2020
  • Figure 4-5: Potential Applications for Artificial Immune Modulation in Medical Field
  • Figure 5-1: Benefits of Clinical Trials in Medical World
  • Figure 5-2: Enrichment & Expansion Process Overview for Artificial Immune Modulation Platform
  • Figure 6-1: Ongoing Clinical Trials for Artificial Immune Modulation Platform by NexImmune
  • Figure 6-2: Robust Pipeline for Artificial Immune Modulation Products
  • Figure 6-3: US - Estimated Acute Myeloid Leukemia Statistics, 2020
  • Figure 6-4: US - Acute Myeloid Leukemia New Cancer Cases Statistics (%), 2020
  • Figure 6-5: US - Acute Myeloid Leukemia Deaths Statistics (%), 2020
  • Figure 6-6: US - Clinical Trial Status for Artificial Immune Modulation, 2020
  • Figure 6-7: US - Multiple Myeloma Cancer Statistics, 2020
  • Figure 6-8: US - Multiple Myeloma Cancer Statistics by Gender, 2020
  • Figure 6-9: US - Clinical Trial Status for Artificial Immune Modulation
  • Figure 7-1: Recent Trends & Opportunity for Artificial Immune Modulation Growth
  • Figure 7-2: Global - Total New Cases of Cancers (Million), 2018
  • Figure 7-3: Global - Total Cancer Deaths (Million), 2018
  • Figure 7-4: Global - New Cases of Multiple Myeloma, 2018
  • Figure 7-5: Global - Total Deaths Due to Multiple Myeloma, 2018
  • Figure 7-6: Clinical Benefits of using Cancer Immunotherapy
  • Figure 7-7: Global - Cancer Immunotherapeutic Market (US$ Billion), 2018-2026
  • Figure 7-8: US - Active, Not Recruiting Clinical Trials for Immunotherapy vs. Other Cancer Treatment Methods, 2020
  • Figure 7-9: Pharmaceutical Companies Investing in Immunotherapy Development
  • Figure 7-10: Global - Roche's Total Immunological Products Sales (US$ Million), 2015 - 2019
  • Figure 7-11: Global - Roche Group Sales Increment (%), 2016 - 2019
  • Figure 7-12: Global - Eli Lilly's Total Immunological Product Sales (US$ Million), 2017 - 2019
  • Figure 7-13: Global - Eli Lilly's Increase in Immunology Revenue due to Taltz (%), 2018 & 2019
  • Figure 7-14: Potential Combinations for Artificial Immune Modulation
  • Figure 8-1: Global - CAR-T Cell Therapy Drug Kymriah Treatment Cost vs. Drug Cost (US$ Million), 2020
  • Figure 8-2: US - Price of CAR-T Cell Therapy Products (US$), 2020
  • Figure 8-3: Global - Kymriah Total Sales (US$ Million), 2018 & 2019
  • Figure 8-4: Global - Yescarta Total Sales (US$ Million), 2018 & 2019
  • Figure 8-5: US - TIL Immunotherapy Minimum & Maximum Treatment Price (US$), 2020
  • Figure 8-6: Immunotherapy Price Comparison
  • Figure 8-7: AIM Therap. . Minimum & Maximum Treatment Price Estimates (US$), 2026
  • Figure 9-1: Cancer Driver for Artificial Immune Modulation Market
  • Figure 9-2: Potential Drivers for Artificial Immune Modulation
  • Figure 9-3: Challenges Associated with Artificial Immune Modulation
  • Figure 10-1: US - Estimated Cancer Care Expenditure by Healthcare (US$ Billion), 2019 & 2026
目次

"Artificial Immune Modulation Therapy Market Opportunity & Clinical Trials Insight 2026" Report Highlights:

  • Immunotherapy Inspired Design for Artificial Immune Modulation (AIM)
  • Artificial Immune Modulations for Various Indications
  • Clinical Trial Insight for AIM: 3 Drugs
  • Expected Price Range for AIM Therapy: > US$ 250,000
  • Market Potential During Five Years of Commercialization: > USD 500 Million
  • Estimated Commercial Opportunity for Artificial Immune Modulation Drugs
  • Future Directions for Artificial Immune Modulation

The research report “Artificial Immune Modulation Therapy Market Opportunity & Clinical Trials Insight 2026” provides comprehensive insight on the applications of artificial immune modulation therapy in today's cancer centric treatment methodologies. This report is focused towards introducing the therapy and the cells that are contributing to the therapy in an elaborated way. Report also discusses about the successful pre-clinical stage results of the therapy and information about its entry in the clinical trial landscape. The research report gives information about the growing interest of the researchers as well as companies towards the possible achievements that the therapy will face in the next few years.

Artificial Immune Modulation (AIM) is among the novel immunotherapy technologies that have been developed keeping in view the rising cases of cancer at global level. As every immunotherapy technology focuses on one major part of immune system, AIM technology's working is also based on artificial antigen presenting cells (aAPC). AIM technology includes the engineering and administrating artificial antigen presenting cells to the patients which further is projected to mimic the core functions of natural antigen presenting cells present inside the human body.

The primary purpose with which artificial antigen presenting cells are administered to the patient involves antigen-specific recognition signal delivery by Major Histone Compatibility molecule loaded with an antigen peptide and also a co-stimulatory signal to direct action by the T cells. Development of another immunotherapy based treatment has caused an expansion of the field, where the contribution of immune cells against diseases is increasing exponentially. Targeting immune cells have projected a novel and regulated version of interaction between the diseased cells and immune system.

An important aspect of AIM therapy is that it provides satisfying nature for reinforcing the working mechanism of immune system against one target which includes the activation of specific types (antigen presenting cells and T-cells) in order to evoke a powerful immune response against specific antigen. It has been few decades since the development of immunotherapy for diseases in which immune system gets artificially activated, but few years since the discovery of AIM. Therefore, adding one more novel technology to this incredibly increases the access of eradicating cancer and other deadly cells from the body.

As per the research findings for analyzing the growing trends of artificial immune modulation, it has been observed that the therapy is prominent towards showing a data that is dominant. As the other immunotherapy products that are available for cancer such as Kymriah and Yescarta and their sales record establishes a hope that the arrival of novel products under AIM therapy will also establish a market that will be more inclined towards AIM. The growing cancer cases and the poor survival rate of other cancer therapies are driving the research world a little more dominant towards AIM.

Although the price of the therapy has not been decided yet but it has been estimated that the therapy will cost approximately the same as the other cancer immunotherapies. The therapy being novel is considered as a fast-growing method in the entire pharmaceutical industry. The therapy is still very young and is evaluated for causing a potential growth, substantive translational and clinical improvements. By observing the future outlook of the cancer cases and the current research activity, it is estimated that the market of AIM will undergo tremendous advancement leading towards the revolution of cancer therapeutics.

Table of Contents

1. Artificial Immune Modulation Nanotechnology Overview

  • 1.1. Introduction to Artificial Immune Modulation Nanotechnology
  • 1.2. Immunotherapy Inspired Design for Artificial Immune Modulation
  • 1.3. Influence of Antigen Presenting Cells on T-cell Activation

2. Role of Nanotechnology in Enriching Artificial Immune Modulation Platform

  • 2.1. Nanoparticles Contributing to Other Immunotherapies Efficiency
  • 2.2 Benefits Associated with Combining Nanotechnology to Artificial Immune Modulation

3. Synthetic Immunology to Engineer Antigen Presenting Cells

  • 3.1. Synthetic Immunology for Already Available Immunotherapy
  • 3.2. Eligibility & Applications of Synthetic Immunology in Artificial Immune Modulation

4. Artificial Immune Modulations for Various Indications

  • 4.1. Immunity - Cancer Cycle Relationship
  • 4.2. Influence of Artificial Immune Modulation Over Cancer
  • 4.3. Influence of Artificial Immune Modulation Against Other Indications

5. T-Cell Enrichment & Expansion (E+E) Technology for Proprietary Artificial Immune Modulation Platform

6. NexImmune Clinical Trials for Artificial Immune Modulation Products

  • 6.1. NEX-001 & NEX-003 for Acute Myeloid Leukemia
    • 6.1.1. Overview
    • 6.1.2. Clinical Insight
  • 6.2. NEX-002 for Multiple Myeloma
    • 6.2.1. Overview
    • 6.2.2. Clinical Insight

7. Recent Trends & Opportunities Available for Expansion of Artificial Immune Modulation Therapy

  • 7.1. Globe Cancer Statistics
  • 7.2. Increasing Popularity of Immunotherapy Treatments
  • 7.3. High Adaptability by Pharmaceutical Companies
  • 7.4. Immunotherapy in Combination with Other Cancer Treatment Methods

8. Estimated Commercial Opportunity for Artificial Immune Modulation Drugs

  • 8.1. Immunotherapies & Price Study for Estimating Artificial Immune Modulation Products Commercial Success
    • 8.1.1. CAR-T Cell Therapy & their Products
    • 8.1.2. Tumor-Infiltrating Lymphocyte Immunotherapy
  • 8.2. AIM Therapy Price Estimates

9. Drivers & Challenges Triggered with the Outcome of Artificial Immune Modulation

  • 9.1. Drivers for Artificial Immune Modulation
  • 9.2. Challenges for Artificial Immune Modulation

10. Future Directions for Artificial Immune Modulation

  • 10.1. Exploring New Avenues for Immunotherapy
  • 10.2. Future Regional Landscape for Artificial Immune Modulation

11. Competitive Landscape

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.